Our path so far
- 2018
PyMES Innovadoras grant
Selected as one of 14 innovative small businesses by the Puerto Rico Industrial Development Company (Government of Puerto Rico).
- 2020
Parallel18 accelerator, Generation 7
Chosen among the Puerto Rican companies in the 7th generation of the Parallel18 acceleration program.
- 2022
P18 Ventures Business Continuity Fund
As a Parallel18 Gen. 7 alumnus, Omics received investment from the P18 Ventures Business Continuity Fund, funded by the Puerto Rico Science Trust.
- 2022
Launch in Puerto Rico and the Dominican Republic
INNOVATIO-ND2 arrives in Puerto Rico, processed by Immuno Reference Lab, and in the Dominican Republic with Macrotech.
- 2022
ISO-certified manufacturing
Manufacturing of INNOVATIO-ND2 is contracted to Syrviatek Laboratories, an ISO-certified facility.
- 2023
Bravo Family Foundation program
Omics took part in the entrepreneurship program of the Bravo Family Foundation, Orlando Bravo's foundation, in Mayagüez.
- 2024
Parallel18 XPAND
Omics took part in Parallel18's XPAND program.
- 2024
Medicare and MCS coverage
INNOVATIO-ND2 (CPT 0385U) is covered by Traditional Medicare and by MCS, in its Advantage and commercial plans.
- 2025
MMM coverage
MMM adds coverage in its Advantage and Vital plans.
